Literature DB >> 7586692

Characterization and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS).

M B Hill1, J L Phipps, R G Malia, M Greaves, P Hughes.   

Abstract

Immunoblotting was used to detect antibodies reacting with membrane and cytosol preparations of human umbilical vein endothelial cells (HUVEC), fibroblasts and a T lymphoma line HUT78 in 18 patients with anticardiolipin antibodies (ACA) (14 of whom had had a thrombotic event), 11 patients with a recent myocardial infarction and 17 controls. Multiple membrane-specific antibodies to HUVEC were found in 10 of the patients with ACA (28 bands) and in nine of the patients with thromboses (27 bands) in contrast to only three of the patients with myocardial infarction (four bands) and one control (one band). The most frequently recognized HUVEC membrane epitopes were at 33 kD (four sera), 61-63 kD (five sera) and 76-79 kD (four sera). Although cross-reactivity with fibroblast and/or HUT78 membranes was seen at 33 kD, binding at 61-63 kD and 76-79 kD was specific for endothelial membranes. Although no correlations with the presence and titre of ACA were seen, HUVEC membrane-specific antibodies showed a correlation with venous thrombotic events.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586692      PMCID: PMC1553403          DOI: 10.1111/j.1365-2249.1995.tb03791.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS.

Authors:  E J BOWIE; J H THOMPSON; C A PASCUZZI; C A OWEN
Journal:  J Lab Clin Med       Date:  1963-09

2.  "Lupus" anticoagulant and thrombosis--possible role of inhibition of prostacyclin formation.

Authors:  L O Carreras; J G Vermylen
Journal:  Thromb Haemost       Date:  1982-08-24       Impact factor: 5.249

3.  Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant.

Authors:  M L Boey; C B Colaco; A E Gharavi; K B Elkon; S Loizou; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08

4.  Thromboembolism in patients with the 'lupus'-type circulating anticoagulant.

Authors:  M Elias; A Eldor
Journal:  Arch Intern Med       Date:  1984-03

5.  A vascular endothelial cell antigen with restricted distribution in human foetal, adult and malignant tissues.

Authors:  Y C Cui; P C Tai; K C Gatter; D Y Mason; C J Spry
Journal:  Immunology       Date:  1983-05       Impact factor: 7.397

6.  Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.

Authors:  P Glas-Greenwalt; K S Kant; A Dosekun; J Frazier; C Allen; V E Pollak
Journal:  J Lab Clin Med       Date:  1985-01

7.  Thrombosis in patients with the lupus anticoagulant.

Authors:  J R Mueh; K D Herbst; S I Rapaport
Journal:  Ann Intern Med       Date:  1980-02       Impact factor: 25.391

8.  Antihistamines and sedation.

Authors:  A N Nicholson
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

9.  Antigenic heterogeneity of vascular endothelium.

Authors:  C Page; M Rose; M Yacoub; R Pigott
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

10.  Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome.

Authors:  N J Lindsey; R A Dawson; F I Henderson; M Greaves; P Hughes
Journal:  Br J Rheumatol       Date:  1993-02
View more
  2 in total

Review 1.  Antiphospholipid antibodies and the endothelium.

Authors:  B J Hunt; M A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

2.  Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension.

Authors:  J Sussman; M Leach; M Greaves; R Malia; G A Davies-Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.